Form 4: Singular Genomics Systems CEO Andrew Spaventa Reports Stock Transactions

CEO Andrew Spaventa reports the acquisition and disposal of Singular Genomics Systems, Inc. common stock related to the vesting and gifting of Restricted Stock Units.

Summary

• On May 12, 2024, Andrew Spaventa, CEO of Singular Genomics Systems, Inc., reported transactions involving the company's common stock.
• These transactions included the acquisition of 57,188 shares through the settlement of vested Restricted Stock Units (RSUs).
• Spaventa also disposed of 57,188 shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
• Following these transactions, Spaventa directly owns 9,766 shares and indirectly owns 4,147,560 shares through The Andrew K. Spaventa Living Trust and 2,569 shares through Axon Holdings, LLC.
• The RSUs vest in 16 equal quarterly installments over four years, starting from February 12, 2024.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Related Party Transactions

• The transfer of shares to The Andrew K. Spaventa Living Trust is a related party transaction.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but it's primarily related to executive compensation.

Key Dates